IDEXX Laboratories announced the expansion of its Fecal Dx antigen testing platform to include detection of taeniid tapeworm species, including Taenia and Echinococcus. The enhanced testing capability can detect up to twice as many infections earlier than fecal flotation alone. Beginning in late June, IDEXX Reference Laboratories customers in the United States and Canada will automatically receive taeniid tapeworm detection within Fecal Dx antigen testing panels and profiles at no additional cost. This upgrade follows the May 19 announcement that the company's SDMA renal biomarker will be integrated into Catalyst CLIPs, making comprehensive kidney function evaluation a standard component of the most used point-of-care chemistry profiles, also at no extra charge for U.S. and Canadian customers starting in June.
IDEXX Laboratories IncExpansion of Fecal Dx antigen testing to detect taeniid tapeworms, enhancing diagnostic capability.